Cargando…

Human immunodeficiency virus type 1 impairs sumoylation

During infection, the human immunodeficiency virus type 1 (HIV-1) manipulates host cell mechanisms to its advantage, thereby controlling its replication or latency, and evading immune responses. Sumoylation is an essential post-translational modification that controls vital cellular activities inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mete, Bilgül, Pekbilir, Emre, Bilge, Bilge Nur, Georgiadou, Panagiota, Çelik, Elif, Sutlu, Tolga, Tabak, Fehmi, Sahin, Umut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860096/
https://www.ncbi.nlm.nih.gov/pubmed/35181598
http://dx.doi.org/10.26508/lsa.202101103
_version_ 1784654596198629376
author Mete, Bilgül
Pekbilir, Emre
Bilge, Bilge Nur
Georgiadou, Panagiota
Çelik, Elif
Sutlu, Tolga
Tabak, Fehmi
Sahin, Umut
author_facet Mete, Bilgül
Pekbilir, Emre
Bilge, Bilge Nur
Georgiadou, Panagiota
Çelik, Elif
Sutlu, Tolga
Tabak, Fehmi
Sahin, Umut
author_sort Mete, Bilgül
collection PubMed
description During infection, the human immunodeficiency virus type 1 (HIV-1) manipulates host cell mechanisms to its advantage, thereby controlling its replication or latency, and evading immune responses. Sumoylation is an essential post-translational modification that controls vital cellular activities including proliferation, stemness, or anti-viral immunity. SUMO peptides oppose pathogen replication and mediate interferon-dependent anti-viral activities. In turn, several viruses and bacteria attack sumoylation to disarm host immune responses. Here, we show that HIV-1 impairs cellular sumoylation and targets the host SUMO E1–activating enzyme. HIV-1 expression in cultured HEK293 cells or in CD4(+) Jurkat T lymphocytes diminishes sumoylation by both SUMO paralogs, SUMO1 and SUMO2/3. HIV-1 causes a sharp and specific decline in UBA2 protein levels, a subunit of the heterodimeric SUMO E1 enzyme, which likely serves to reduce the efficiency of global protein sumoylation. Furthermore, HIV-1–infected individuals display a significant reduction in total leukocyte sumoylation that is uncoupled from HIV-induced cytopenia. Because sumoylation is vital for immune function, T-cell expansion and activity, loss of sumoylation during HIV disease may contribute to immune system deterioration in patients.
format Online
Article
Text
id pubmed-8860096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Life Science Alliance LLC
record_format MEDLINE/PubMed
spelling pubmed-88600962022-03-11 Human immunodeficiency virus type 1 impairs sumoylation Mete, Bilgül Pekbilir, Emre Bilge, Bilge Nur Georgiadou, Panagiota Çelik, Elif Sutlu, Tolga Tabak, Fehmi Sahin, Umut Life Sci Alliance Research Articles During infection, the human immunodeficiency virus type 1 (HIV-1) manipulates host cell mechanisms to its advantage, thereby controlling its replication or latency, and evading immune responses. Sumoylation is an essential post-translational modification that controls vital cellular activities including proliferation, stemness, or anti-viral immunity. SUMO peptides oppose pathogen replication and mediate interferon-dependent anti-viral activities. In turn, several viruses and bacteria attack sumoylation to disarm host immune responses. Here, we show that HIV-1 impairs cellular sumoylation and targets the host SUMO E1–activating enzyme. HIV-1 expression in cultured HEK293 cells or in CD4(+) Jurkat T lymphocytes diminishes sumoylation by both SUMO paralogs, SUMO1 and SUMO2/3. HIV-1 causes a sharp and specific decline in UBA2 protein levels, a subunit of the heterodimeric SUMO E1 enzyme, which likely serves to reduce the efficiency of global protein sumoylation. Furthermore, HIV-1–infected individuals display a significant reduction in total leukocyte sumoylation that is uncoupled from HIV-induced cytopenia. Because sumoylation is vital for immune function, T-cell expansion and activity, loss of sumoylation during HIV disease may contribute to immune system deterioration in patients. Life Science Alliance LLC 2022-02-18 /pmc/articles/PMC8860096/ /pubmed/35181598 http://dx.doi.org/10.26508/lsa.202101103 Text en © 2022 Mete et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Articles
Mete, Bilgül
Pekbilir, Emre
Bilge, Bilge Nur
Georgiadou, Panagiota
Çelik, Elif
Sutlu, Tolga
Tabak, Fehmi
Sahin, Umut
Human immunodeficiency virus type 1 impairs sumoylation
title Human immunodeficiency virus type 1 impairs sumoylation
title_full Human immunodeficiency virus type 1 impairs sumoylation
title_fullStr Human immunodeficiency virus type 1 impairs sumoylation
title_full_unstemmed Human immunodeficiency virus type 1 impairs sumoylation
title_short Human immunodeficiency virus type 1 impairs sumoylation
title_sort human immunodeficiency virus type 1 impairs sumoylation
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860096/
https://www.ncbi.nlm.nih.gov/pubmed/35181598
http://dx.doi.org/10.26508/lsa.202101103
work_keys_str_mv AT metebilgul humanimmunodeficiencyvirustype1impairssumoylation
AT pekbiliremre humanimmunodeficiencyvirustype1impairssumoylation
AT bilgebilgenur humanimmunodeficiencyvirustype1impairssumoylation
AT georgiadoupanagiota humanimmunodeficiencyvirustype1impairssumoylation
AT celikelif humanimmunodeficiencyvirustype1impairssumoylation
AT sutlutolga humanimmunodeficiencyvirustype1impairssumoylation
AT tabakfehmi humanimmunodeficiencyvirustype1impairssumoylation
AT sahinumut humanimmunodeficiencyvirustype1impairssumoylation